Toggle navigation
Campus Access
About MPG.eBooks
Skip to content
Search Tips
Home
>
Search:
Language
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
All Fields
Title
Person
Topic
ISBN/ISSN
Year
Collection
Advanced
Retain my current filters
author_facet:"CADTH Canadian Drug Expert Committee"
author_facet:"Canadian Agency for Drugs and Technologies in Health"
dewey-ones:"140 - Specific philosophical schools"
Showing
1
-
19
of
19
Search:
''
,
query time: 0.01s
Book List
0
Sort:
Relevance
Year Descending
Year Ascending
Author
Title
Read Now
1
Clinical review report: Brolucizumab (Beovu) (Novartis Pharmaceuticals Canada Inc.) : indication : treatment of neovascular (wet) age-related macular degeneration (AMD)
Published 2020
Canadian Agency for Drugs and Technologies in Health
Read Now
2
CADTH Canadian Drug Expert Committee recommendation: Eculizumab (Soliris -- Alexion Pharma Canada Corp.) : indication : adult patients with refractory generalized myasthenia gravis
Published 2020
Canadian Agency for Drugs and Technologies in Health
Read Now
3
CADTH Canadian Drug Expert Committee recommendation: Eculizumab (Soliris - Alexion Pharma Canada Corp.) : indication : the treatment of neuromyelitis optica spectrum disorder (NMOS...
Published 2020
Canadian Agency for Drugs and Technologies in Health
Read Now
4
CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: ankylosing spondylitis
Published 2020
CADTH
Read Now
5
CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: ankylosing spondylitis
Published 2020
CADTH
Read Now
6
CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis
Published 2016
Canadian Agency for Drugs and Technologies in Health
Read Now
7
CADTH Canadian Drug Expert Committee recommendation: Tocilizumab (Actemra - Hoffmann-La Roche Limited) : indication : giant cell arteritis
Published 2018
CADTH
Read Now
8
CADTH Canadian Drug Expert Committee final recommendation: Sarilumab (Kevzara -- Sanofi Genzyme) : indication: rheumatoid arthritis
Published 2017
Canadian Agency for Drugs and Technologies in Health
Read Now
9
CADTH Canadian Drug Expert Committee recommendation: Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) : indication : treatment of adult patients with relapsing-remitting multiple...
Published 2017
Canadian Agency for Drugs and Technologies in Health
Read Now
10
CADTH Canadian Drug Expert Committee recommendation: Brolucizumab (Beovu -- Novartis Pharmaceuticals Canada Inc.) : indication : treatment of neovascular (wet) age-related macular...
Published 2020
Canadian Agency for Drugs and Technologies in Health
Read Now
11
CADTH Canadian drug expert committee recommendation: Burosumab (Crysvita -- Kyowa Kirin Limited) : indication : treatment of x-linked hypophosphatemia
Published 2020
Canadian Agency for Drugs and Technologies in Health
Read Now
12
CADTH Canadian Drug Expert Committee recommendation: Brolucizumab (Beovu -- Novartis Pharmaceuticals Canada Inc.) : indication : treatment of neovascular (wet) age-related macular...
Published 2020
Canadian Agency for Drugs and Technologies in Health
Read Now
13
CADTH Canadian Drug Expert Committee recommendation: Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) : indication : treatment of adult patients with relapsing-remitting multiple...
Published 2017
Canadian Agency for Drugs and Technologies in Health
Read Now
14
CADTH Canadian Drug Expert Committee recommendation: Tocilizumab (Actemra - Hoffmann-La Roche Limited) : indication : giant cell arteritis
Published 2018
CADTH
Read Now
15
Clinical review report: Brolucizumab (Beovu) (Novartis Pharmaceuticals Canada Inc.) : indication : treatment of neovascular (wet) age-related macular degeneration (AMD)
Published 2020
Canadian Agency for Drugs and Technologies in Health
Read Now
16
CADTH Canadian Drug Expert Committee recommendation: Ofatumumab (Kesimpta -- Novartis Hharmaceuticals Canada Inc.) : indication : multiple sclerosis, relapsing-remitting
Published 2021
Canadian Agency for Drugs and Technologies in Health
Read Now
17
CADTH Canadian drug expert committee recommendation: Burosumab (Crysvita -- Kyowa Kirin Limited) : indication : treatment of x-linked hypophosphatemia
Published 2020
Canadian Agency for Drugs and Technologies in Health
Read Now
18
CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis
Published 2016
Canadian Agency for Drugs and Technologies in Health
Read Now
19
CADTH Canadian Drug Expert Committee final recommendation: Sarilumab (Kevzara -- Sanofi Genzyme) : indication: rheumatoid arthritis
Published 2017
Canadian Agency for Drugs and Technologies in Health
Back
Narrow Search
Remove Filters
Clear Filter
Author: CADTH Canadian Drug Expert Committee
Clear Filter
Author: Canadian Agency for Drugs and Technologies in Health
Clear Filter
Classification: 140 - Specific philosophical schools
Year of Publication
From:
To:
Classification
140 - Specific philosophical schools
610 - Medicine & health
16
330 - Economics
8
700 - The arts; fine & decorative arts
4
Language
English
19
Collection
National Center for Biotechnology Information
19
Author
CADTH Canadian Drug Expert Committee
Canadian Agency for Drugs and Technologies in Health
Search Tools
Get RSS Feed
Share Search
https://ebooks.mpdl.mpg.de/ebooks/Search/Results?filter%5B%5D=author_facet%3A%22CADTH+Canadian+Drug+Expert+Committee%22&filter%5B%5D=author_facet%3A%22Canadian+Agency+for+Drugs+and+Technologies+in+Health%22&filter%5B%5D=dewey-ones%3A%22140+-+Specific+philosophical+schools%22&type=AllFields
Send by Email
×
Loading...